Ryan Cirz has spent the past 19 years focused on the discovery and development of novel antibacterials for high unmet medical needs. At Achaogen, a San Francisco-based biotech which he helped found, he witnessed firsthand the evolution of both the pathogens we were targeting and the regulatory framework to obtain market authorization for new, innovative products. He then witnessed the financial collapse of one of the most prolific research and development organizations in the sector a mere 9 months after FDA approval and launch of its first commercial antibacterial. He spent the last year at Achaogen engaging with the field team, end-users, charities/NGOs, and government stakeholders to seek to understand the driving forces behind the ultimate collapse. He carried those learnings to Revagenix, Inc. where he continues to focus on extreme unmet medical needs and the barriers to patient access that confound the antibacterial field to this day.